JP2019014747A - Mesenchymal stem cells and uses thereof - Google Patents

Abstract

To provide methods of treating autoimmune diseases, allergic diseases, cancer or inflammatory diseases in an animal, methods of promoting wound healing, and methods of promoting angiogenesis in an organ or tissue of an animal.SOLUTION: Isolated, allogeneic, genetically unmanipulated mesenchymal stem cells are administered in an effective amount.SELECTED DRAWING: None

Description

  The present invention relates to mesenchymal stem cells. In particular, the present invention relates to novel uses of mesenchymal stem cells, including promoting angiogenesis in various tissues and organs, treating autoimmune diseases, treating allergic reactions, treating cancer, treating inflammatory diseases, and promoting recovery. .

  Mesenchymal stem cells (MSCs) are pluripotent stem cells that can be easily differentiated into lineages including osteoblasts, myocytes, chondrocytes and adipocytes (Non-patent Document 1, Non-patent Document 2, Non-patent Document 3). ). MSCs in muscle (Non-patent document 4), neuron-like precursors (Non-patent document 5, Non-patent document 6), cardiomyocytes (Non-patent document 7, Non-patent document 8), and possibly other cell types The ability to differentiate into has been demonstrated by in vitro studies. Furthermore, MSCs are considered to provide a feeder cell layer effective for the expansion of hematopoietic stem cells and embryonic stem cells (Non-patent Documents 9 and 10). Recent studies using various animal models have shown that MSCs can be useful for the repair or regeneration of damaged bone, cartilage, meniscus or myocardial tissue (11). Non-patent document 12, Non-patent document 13, Non-patent document 14, Non-patent document 15). Several researchers use MSCs, osteogenesis imperfecta (Non-patent document 16), Parkinson's syndrome (Non-patent document 17), spinal cord injury (Non-patent document 18, Non-patent document 19), and heart disease (Non-patent document) 20, promising results have been shown for transplantation into animal disease models including non-patent literature 21). Importantly, it is also promising in clinical trials for osteogenesis imperfecta (Non-patent document 22, Non-patent document 23) and enhanced transplantation of heterogeneous bone marrow transplantation (non-patent document 24, non-patent document 25). Results have been reported.

  MSCs express major histocompatibility complex (MHC) class I antigens on their surface, but MHC class II is restricted (Non-patent document 26, Non-patent document 27) and does not express B7 or CD40 costimulatory molecules. (Non-patent document 28), which indicates that these cells have a low immunogenic phenotype (Non-patent document 29). MSCs also suppress the T cell proliferative response in an MHC-independent manner (Non-Patent Document 30, Non-Patent Document 31, Non-Patent Document 32). The immunological properties of these MSCs can enhance their transplantation and limit the recipient's immune system's ability to recognize and reject allogeneic cells after transplantation. MSCs are desirable stem cells for cell transplantation studies because they generate factors that regulate immune responses and support hematopoiesis, as well as the ability to differentiate into appropriate cell lines under local stimulation (Non-Patent Document 33, Non-Patent Document 33). Patent Document 34).

Pittenger, et al. , Science, Vol. 284, pg. 143 (1999) Haynesworth, et al. , Bone, Vol. 13, pg. 69 (1992) Prochop, Science, Vol. 276, pg. 71 (1997) Wakitani, et al. , Muscle Nerve, Vol. 18, pg. 1417 (1995) Woodbury, et al. , J .; Neurosci. Res. , Vol. 69, pg. 908 (2002) Sanchez-Ramos, et al. , Exp. Neurol. , Vol. 171, pg. 109 (2001) Toma, et al. , Circulation, Vol. 105, pg. 93 (2002) Fakuda, Artif. Organs, Vol. 25, pg. 187 (2001) Eaves, et al. , Ann. N. Y. Acad. Sci. , Vol. 938, pg. 63 (2001) Wagers, et al. , Gene Therapy, Vol. 9, pg. 606 (2002) Dekok, et al. , Clin. Oral Implants Res. , Vol. 14, pg. 481 (2003) Wu, et al. , Transplantation, Vol. 75, pg. 679 (2003) Noel, et al. Curr. Opin. Investig. Drugs, Vol. 3, pg. 1000 (2002) Ballas, et al. , J .; Cell. Biochem. Suppl. , Vol. 38, pg. 20 (2002) Mackenzie, et al. , Blood Cells Mol. Dis. , Vol. 27 (2002) Pereira, et al. , Proc. Nat. Acad. Sci. , Vol. 95, pg. 1142 (1998) Schwartz, et al. , Hum. Gene Ther. , Vol. 10, pg. 2539 (1999) Chopp, et al. , Neuroport, Vol. 11, pg. 3001 (2000) Wu, et al. , J .; Neurosci. Res. , Vol. 72, pg. 393 (2003) Tomita, et al. , Circulation, Vol. 100, pg. 247 (1999) Shake, et al. , Ann. Thorac. Surg. , Vol. 73, pg. 1919 (2002) Horwitz, et al. , Blood, Vol. 97, pg. 1227 (2001) Horowitz, et al. Proc. Nat. Acad. Sci. , Vol. 99, pg. 8932 (2002) Frassoni, et al. , Int. Society for Cell Therapy, SA006 (abstract) (2002) Koc, et al. , J .; Clin. Oncol. , Vol. 18, pg. 307 (2000) Le Blanc, et al. , Exp. Hematol. , Vol. 31, pg. 890 (2003) Potian, et al. , J .; Immunol. , Vol. 171, pg. 3426 (2003) Majumdar, et al. , J .; Biomed. Sci. , Vol. 10, pg. 228 (2003) Tse, et al. , Transplantation, Vol. 75, pg. 389 (2003) Bartholomew, et al. , Exp. Hematol. , Vol. 30, pg. 42 (2002) Devine, et al. Cancer J .; , Vol. 7, pg. 576 (2001) DiNicola, et al. , Blood, Vol. 99, pg. 3838 (2002) Majumdar, et al. , Hematother. Stem Cell Res. , Vol. 9, pg. 841 (2000) Haynesworth, et al. , J .; Cell. Physiol. , Vol. 166, pg. 585 (1996)

  Applicants have now investigated the interaction of mesenchymal stem cells with isolated immune cell populations including dendritic cells (DC1 and DC2), effector T cells (Th1 and Th2), and NK cells. Based on the interaction, Applicants have discovered that mesenchymal stem cells can regulate the production of various factors that can regulate several stages of the immune response process. Thus, mesenchymal stem cells can be used to treat diseases, conditions and disorders involving the immune system or to treat diseases, conditions and disorders involving inflammation or allergic reactions. Said diseases, conditions and disorders involve autoimmune diseases, allergies, arthritis, inflamed wounds, alopecia areata (bald baldness), gingivitis and periodontitis, including periodontitis, and immune response Including but not limited to other diseases, conditions or disorders.

Diagram explaining the regulation of dendritic cell action of MSCs Diagram explaining the regulation of dendritic cell action of MSCs Diagram explaining the regulation of dendritic cell action of MSCs Diagram illustrating suppression of pro-inflammatory effector T cell action of MSCs Diagram illustrating suppression of pro-inflammatory effector T cell action of MSCs Diagram illustrating suppression of pro-inflammatory effector T cell action of MSCs The figure explaining the induction | guidance | derivation of the increase in the Treg cell population number of MSCs, and the increase in GITR expression The figure explaining the induction | guidance | derivation of the increase in the number of Treg cell populations of MSCs, and the increase in GITR expression. Diagram illustrating PGE2 production of MSCs and inhibition of PGE2 abolishing MSC-mediated immunomodulatory action Diagram illustrating PGE2 production of MSCs and inhibition of PGE2 abolishing MSC-mediated immunomodulatory action Diagram illustrating PGE2 production of MSCs and inhibition of PGE2 abolishing MSC-mediated immunomodulatory action Diagram illustrating PGE2 production of MSCs and inhibition of PGE2 abolishing MSC-mediated immunomodulatory action Diagram illustrating increased constitutive MSC cytokine secretion in the presence of allogeneic PBMCs Diagram illustrating suppression of mitogen-induced T cell proliferation in a dose-dependent manner of MSCs System diagram of MSC mechanism of action

  Furthermore, mesenchymal stem cells are thought to stimulate peripheral blood mononuclear cells (PBMCs) to produce vascular endothelial growth factor, or VEGF, that promotes angiogenesis by promoting the formation of new blood vessels.

Furthermore, mesenchymal stem cells are thought to stimulate dendritic cells (DCs) to produce interferon-beta (INF-β) that enhances immunity against cancer suppression and viral infection.

  In accordance with one aspect of the present invention, a method for treating an autoimmune disease in an animal is provided. The method includes administering mesenchymal stem cells to the animal in an amount effective to treat the animal's autoimmune disease.

  Although the scope of this aspect of the invention should not be limited to any theoretical reasoning, at least one mechanism by which mesenchymal stem cells suppress autoimmune diseases is regulatory T cells (Treg cells) and / or This is thought to be due to the release of interleukin 10 (IL-10) from dendritic cells (DC).

  Autoimmune diseases that can be treated according to the present invention are multiple sclerosis, type 1 diabetes, rheumatoid arthritis, uveitis, autoimmune thyroid disease, inflammatory bowel disease, autoimmune lymphoproliferative syndrome (ALPS), demyelination Diseases include, but are not limited to, autoimmune encephalomyelitis, autoimmune gastritis (AIG), and autoimmune glomerular disease. However, it is to be understood that the scope of the present invention is not limited to the treatment of the specific autoimmune diseases disclosed herein.

  In one example, the animal to which mesenchymal stem cells are administered is a mammal. The mammal can be a primate, including human and non-human primates.

  Typically, mesenchymal stem cell (MSC) therapy is based on, for example, the following procedures: collection of MSC-containing tissues, isolation and growth of MSCs, and to animals with or without biochemical or genetic manipulation. Administration of MSCs.

  The mesenchymal stem cells administered can be a homogeneous composition or a mixed cell population enriched in MSCs. A uniform mesenchymal stem cell composition can be obtained by culturing adherent bone marrow cells or periosteum cells. The mesenchymal stem cell composition can be obtained by culturing adhesive bone marrow cells or periosteum cells. Mesenchymal stem cells can also be identified by specific cell surface markers identified with unique monoclonal antibodies. A method for obtaining a cell population rich in mesenchymal stem cells is disclosed, for example, in US Pat. No. 5,486,359. Alternative resources for mesenchymal stem cells include, but are not limited to, blood, skin, umbilical cord blood, muscle, fat, bone, and perichondrium.

  Mesenchymal stem cells can be administered in various ways. Mesenchymal stem cells can be administered systemically by intravenous, intraarterial, or intraperitoneal administration.

  Mesenchymal stem cells can be obtained from a wide variety of resources including autologous, allogeneic and xenogeneic.

Mesenchymal stem cells are administered to the animal in an amount effective to administer the autoimmune disease. Mesenchymal stem cells can be administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg, preferably about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The amount of mesenchymal stem cells administered depends on a variety of factors, including age, weight, patient sex, autoimmune disease being treated, and its scope and severity.

  Mesenchymal stem cells can be administered in conjunction with a pharmaceutically acceptable carrier. For example, mesenchymal stem cells can be administered as a cell suspension in a pharmaceutically acceptable liquid medium for injection.

In accordance with another aspect of the present invention, a method for treating an inflammatory response in an animal is provided. The method includes administering mesenchymal stem cells to the animal in an amount effective to treat the inflammatory response in the animal.

  Although the scope of this aspect of the invention should not be limited to any theoretical reasoning, mesenchymal stem cells promote maturation of T cells into regulatory T cells (Tregs), thereby controlling the inflammatory response I think that. It is also believed that mesenchymal stem cells suppress T helper 1 cells (Th1 cells), thereby reducing the expression of interferon γ (INF-γ) in certain inflammatory reactions, such as those associated with psoriasis.

  In one example, the inflammatory response that can be treated is that associated with psoriasis.

  In other examples, mesenchymal stem cells can be administered to an animal such that the mesenchymal stem cells contact microglia (microglia) and / or astrocytes in the brain to reduce inflammation. Thus, mesenchymal stem cells suppress neurodegeneration caused by activated glial cells (activated glial cells) in diseases or disorders such as Alzheimer's disease, Parkinson's disease, cerebral infarction or brain cell damage.

  Also, in other embodiments, the mesenchymal stem cells may contact the keratinocytes and Langerhans cells in the epidermis of the skin to alleviate inflammation that may occur in psoriasis, chronic dermatitis and contact dermatitis. Can be administered to animals. Although this example should not be limited to any theoretical reasoning, mesenchymal stem cells contact epidermal keratinocytes and Langerhans cells, altering T cell receptors and cytokine secretion profiles, and tumor necrosis factor It is thought that the expression of alpha (TNF-α) decreases and the regulatory T cell (Treg cell) population increases.

  In further examples, mesenchymal stem cells are used in osteoarthritis, rheumatoid arthritis and the website www. arthritis. It can be used to alleviate inflammation in the bone that occurs in arthritis and arthritis-like conditions including but not limited to other joint diseases listed in org / conditions / disesees. Although the scope of this example is not intended to be limited to any theoretical reasoning, it is believed that mesenchymal stem cells can suppress interleukin-17 secretion by memory T cells in synovial fluid.

  In other examples, mesenchymal stem cells can be used to alleviate inflammation in the gastrointestinal tract and liver in inflammatory bowel disease and chronic hepatitis, respectively. Although the scope of this aspect of the invention is not intended to be limited to any theoretical reasoning, mesenchymal stem cells have increased secretion of interleukin-10 (IL-10) and regulatory T cells (Treg cells). It is thought to promote the occurrence of

  In other examples, mesenchymal stem cells can be used to suppress excessive neutrophil activation and macrophage activation in pathologies such as sepsis and trauma including burns, surgery, transplantation, etc. . The scope of this example should not be limited to any theoretical reasoning, but it is believed that mesenchymal stem cells promote secretion of inhibitory cytokines such as IL-10 and suppress macrophage migration inhibitory factors.

  In other embodiments, the mesenchymal stem cells are cornea, lens, pigment epithelium, eyes including retina, brain, spinal cord, pregnancy uterus, and placenta, ovary, testis, adrenal cortex, liver, hair follicles, etc. Can be used to reduce inflammation at immunologically privileged sites. Although the scope of this example should not be limited to any theoretical reasoning, it is believed that mesenchymal stem cells promote secretion of inhibitory cytokines such as IL-10 and generation of Treg cells.

In yet other embodiments, the mesenchymal stem cells may be end stage renal failure (e.g., during dialysis and / or glomerulonephritis).
ESRD) can be used to regulate infection. Although the scope of this example should not be limited to any theoretical reasoning, peripheral blood mononuclear cells so that mesenchymal stem cells express vascular endothelial growth factor, VEGF, that promotes glomerular structure formation It is thought to induce.

  In further examples, mesenchymal stem cells can be used to control viral infections such as influenza, hepatitis C, herpes simplex virus, vaccinia virus infection, and Epstein-Barr virus. Although the scope of this example should not be limited to any theoretical reasoning, it is believed that mesenchymal stem cells promote secretion of interferon-beta (IFN-β).

  In yet another example, mesenchymal stem cells can be used to control parasitic infections such as Leishmania infection and Helicobacter infection. The scope of this example should not be limited to any theoretical reasoning, but mesenchymal stem cells modulate the response by T helper 2 (Th2) cells, thereby increasing the production of immunoglobulin E by β cells It is thought to promote.

  However, it should be understood that the scope of this aspect of the invention should not be limited to the treatment of any particular inflammatory response.

  Mesenchymal stem cells can be administered to animals, including humans and non-human primates, as described above.

  In addition, the mesenchymal stem cells can be administered systemically as described above. Alternatively, in the case of osteoarthritis or rheumatoid arthritis, mesenchymal stem cells can be administered directly to the arthritic site.

Mesenchymal stem cells are administered in an amount effective to treat the inflammatory response in the animal. Mesenchymal stem cells can be administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg, preferably about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The exact dose of mesenchymal stem cells to be administered depends on a variety of factors, including age, weight, patient sex, the inflammatory response being treated, and its scope and severity.

  Mesenchymal stem cells can be administered in conjunction with a pharmaceutically acceptable carrier as described above.

  In accordance with yet another aspect of the invention, there are provided methods of treating cancer in animals. The method comprises administering to the animal mesenchymal stem cells in an amount effective to treat the animal's cancer.

  Although the scope of this aspect of the invention should not be limited to any theoretical reasoning, it is believed that mesenchymal stem cells interact with dendritic cells resulting in IFN-β secretion and acting as tumor suppressors. . Cancers that can be treated include, but are not limited to, hepatocellular carcinoma, cervical cancer, pancreatic cancer, prostate cancer, fibrosarcoma, medulloblastoma, and astrocytoma. However, it should be understood that the scope of the invention should not be limited to any particular cancer.

  The animal can be a mammal, including humans and non-human primates, as described above.

Mesenchymal stem cells are administered to the animal in an amount effective to treat cancer in the animal. Usually, mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg, preferably about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The The exact amount of mesenchymal stem cells to be administered depends on a variety of factors, including age, weight, patient sex, the type of cancer being treated, and its scope and severity.

As described above, mesenchymal stem cells are administered in combination with a pharmaceutically acceptable carrier and can be administered systemically. Alternatively, mesenchymal stem cells can be administered directly to the cancer being treated.

  In accordance with yet another aspect of the present invention, there are provided methods of treating allergic diseases in animals. The method comprises administering mesenchymal stem cells to the animal in an amount effective to treat the animal's allergic disease.

  The scope of this aspect of the invention should not be limited to any theoretical reasoning, but when mesenchymal stem cells are administered after an acute allergic reaction, they result in mast cell activation and suppression of degranulation it is conceivable that. In addition, mesenchymal stem cells down-regulate basophil activation, and cytokines such as TNF-α, interleukin-8 and monocyte chemotactic proteins, or lipid mediators such as chemokines such as MCP-1 and leukotrienes It is also considered to suppress major mediators such as histamine, heparin, chondroitin sulfate, and cathepsin.

  Allergic diseases that can be treated include, but are not limited to, asthma, allergic rhinitis, atopic dermatitis, and contact dermatitis. However, it should be understood that the scope of the present invention should not be limited to any particular allergic disease.

The mesenchymal stem cells are administered to the animal in an amount effective to treat the animal's allergic disease. The animal can be a mammal. The mammal can be a primate, including human and non-human primates. Usually, mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg, preferably about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The The exact dosage depends on a variety of factors, including age, weight, patient sex, allergic disease being treated, and its scope and severity.

  Mesenchymal stem cells can be administered in conjunction with a pharmaceutically acceptable carrier as described above. Mesenchymal stem cells can be administered systemically, for example, by intravenous administration or intraarterial administration.

  In accordance with a further aspect of the invention, a method for promoting wound healing in an animal is provided. The method includes administering to the animal mesenchymal stem cells in an amount effective to promote wound healing in the animal.

  Although the scope of the present invention should not be limited to any theoretical reasoning, it is believed that mesenchymal stem cells cause Treg cells and dendritic cells to release interleukin-10 (IL-10) as described above. . IL-10 inhibits or regulates inflammation in the wound, thereby promoting wound healing.

  Furthermore, mesenchymal stem cells can promote wound healing and fracture healing by inducing secretory factors by other cell types. For example, mesenchymal stem cells are prostaglandin E2 (PGE2) mediated release of vascular endothelial growth factor (VEGF) by peripheral blood mononuclear cells (PBMCs) and growth hormone, insulin, insulin-like growth factor 1 (IGF-1) ), Insulin-like growth factor binding protein 3 (IGFBP-3), and PGE2-mediated release of endothelin-1.

Mesenchymal stem cells are administered to the animal in an amount effective to promote animal wound healing. The animal can be a mammal. The mammal can also be a primate, including human and non-human primates. Usually, mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg, preferably about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The The exact amount of mesenchymal stem cells to be administered depends on a variety of factors, including age, weight, patient sex, and the extent and severity of the wound being treated.

  Mesenchymal stem cells can be administered in conjunction with a pharmaceutically acceptable carrier as described above. Mesenchymal stem cells can be administered systemically as described above. Alternatively, the mesenchymal stem cells can be administered directly to the wound, such as a sachet or storage container fluid containing the mesenchymal stem cells.

  In accordance with another aspect of the present invention, a method for treating or preventing fibrosis in an animal is provided. The method includes administering to the animal mesenchymal stem cells in an amount effective to treat or prevent fibrosis in the animal.

  Mesenchymal stem cells are administered to animals to treat or prevent any type of animal fibrosis including but not limited to cirrhosis, renal fibrosis associated with end stage renal failure, and pulmonary fibrosis. obtain. It should be understood that the scope of the present invention should not be limited to any particular type of fibrosis.

Mesenchymal stem cells are administered to the animal in an amount effective to treat or prevent fibrosis in the animal. The animal can be a mammal. The mammal can also be a primate, including human and non-human primates. Usually, mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg, preferably about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The The exact amount of mesenchymal stem cells to be administered depends on a variety of factors, including age, weight, patient gender, and the extent and severity of fibrosis to be treated or prevented.

  Mesenchymal stem cells can be administered in conjunction with a pharmaceutically acceptable carrier as described above. Mesenchymal stem cells can be administered systemically as described above.

  Another object of the present invention is to promote angiogenesis in animal tissues or organs. Here, the tissue or organ is in need of angiogenesis.

  Thus, according to a further aspect of the invention, a method is provided for promoting angiogenesis in an animal organ or tissue. The method includes administering to the animal mesenchymal stem cells in an amount effective to promote angiogenesis in the organ or tissue of the animal.

  Angiogenesis is the formation of new blood vessels from an existing microvascular bed.

  Induction of angiogenesis can be used to treat coronary artery dysfunction and peripheral artery dysfunction. Thus, it can be a non-invasive curative method for the treatment of coronary artery disease, ischemic heart disease, and peripheral arterial disease. Angiogenesis can be involved in the treatment of diseases and disorders in tissues and organs other than the heart and in the development and / or maintenance of organs other than the heart. Angiogenesis can be involved in the treatment of internal and external wounds and skin ulcers. Angiogenesis is also involved in lung implantation, placental growth, and development of the fetal vasculature. Angiogenesis is extremely important for the connection between cartilage resorption and bone formation, and is also extremely important for accurate growth plate morphogenesis.

  Furthermore, angiogenesis is necessary for the sufficient formation and maintenance of highly metabolic organs such as the liver, where a dense vascular network is necessary to provide sufficient nutrient and gas transport.

  Mesenchymal stem cells can be administered to tissues or organs in need of angiogenesis by various methods. Mesenchymal stem cells can be administered systemically by intravenous, intraarterial or intraperitoneal administration. Alternatively, mesenchymal stem cells can be administered directly to a tissue or organ that requires angiogenesis, for example, by direct injection into the tissue or organ that requires angiogenesis.

  Mesenchymal stem cells can be obtained from a wide variety of resources including autologous, allogeneic and xenogeneic.

  While the scope of the present invention should not be limited to any theoretical reasoning, it is likely that mesenchymal stem cells produce vascular endothelial growth factor, VEGF, that promotes the formation of new blood vessels when administered to animals. It is thought to stimulate peripheral blood mononuclear cells (PBMCs).

  In one example, the animal is a mammal. The mammal can be a primate, including human and non-human primates.

  In accordance with the present invention, mesenchymal stem cells can be used in the treatment, reduction or prevention of any disease or disorder that can be reduced, treated or prevented through angiogenesis. Thus, for example, mesenchymal stem cells can be administered to animals to treat arterial occlusions including those in the extremities, ie, arms, legs, hands, feet, and neck or various organs. For example, mesenchymal stem cells can be used to treat arterial occlusion of arteries distributed in the brain, thereby treating or preventing cerebral infarction. Mesenchymal stem cells can also be used to treat corneal blood vessels during fetal and postnatal life. It can also be used to effect glomerular structure formation. In other embodiments, the mesenchymal stem cells are used to treat both internal and external wounds, and include, but are not limited to, skin ulcers caused by diseases such as diabetes and sickle cell anemia. Alternatively, it can be used to treat skin ulcers found in the arms.

  Furthermore, since angiogenesis is involved in embryo implantation and placenta formation, mesenchymal stem cells can be used to promote embryo implantation and to prevent miscarriage.

  In addition, mesenchymal stem cells can be administered to prenatal animals, including humans, to promote vasculature development in prenatal animals.

  In other examples, mesenchymal stem cells can be administered to postnatal or prenatal animals to promote cartilage resorption and bone formation and to promote accurate growth plate morphogenesis.

Mesenchymal stem cells are administered in an amount effective to promote angiogenesis in the animal. Mesenchymal stem cells can be administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg, preferably about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The amount of mesenchymal stem cells to be administered depends on a variety of factors, including age, weight, gender of the patient, the disease or disorder to be treated, reduced or prevented, and its scope and severity.

  Mesenchymal stem cells can be administered in conjunction with a pharmaceutically acceptable carrier. For example, mesenchymal stem cells can be administered as a cell suspension in a pharmaceutically acceptable liquid medium for injection. The injection may be local, i.e. directly into the tissue or organ in need of angiogenesis, or systemic.

Mesenchymal stem cells can be genetically modified with one or more polynucleotides encoding a therapeutic factor. The polynucleotide may comprise any suitable expression medium (expression
vehicles) can be delivered to mesenchymal stem cells. Expression media that can be used to genetically modify mesenchymal stem cells include, but are not limited to, retroviral vectors, adenoviral vectors, and adeno-associated viral vectors.

  The selection of an appropriate polynucleotide encoding a therapeutic factor will depend on a variety of factors, including the disease or disorder being treated and its scope and severity. Polynucleotides encoding therapeutic factors and suitable expression media are further disclosed in US Pat. No. 6,355,239.

  When mesenchymal stem cells are used in the above-mentioned treatments, normal in this field, including but not limited to drugs such as growth factors, cytokines, anti-inflammatory agents, and dendritic cells Can be used in combination with other therapeutic factors known to those with knowledge of and, if necessary, with a soluble carrier for cells such as hyaluronic acid, or collagen, gelatin, or other biocompatible polymers It should be understood that it can be administered in conjunction with solids such as

  It should be understood that the methods disclosed herein may be implemented in a number of ways and with various modifications and substitutions well known in the art. Also, any theory describing the mechanism of action or interaction between cell types should not be construed to limit the invention to any method, but is presented so that the method of the invention can be more fully understood. Can be recognized.

The present invention will be disclosed with reference to the drawings. here,
Fig. 1 Modulation of dendritic cell action of MSCs (A) Flow cytometric analysis of mature monocyte DC1 cells using antibodies against HLA-DR and CD11c, and antibodies against HLA-DR and CD123 (IL-3 receptor) Flow cytometric analysis of plasmacytoid DC2 cells. (--- (dashed line)): isotype control; (___ (solid line)): FITC / PE-conjugated antibody. (B) MSCs suppress TNF-α secretion from activated DC1 and DC2 (first y-axis) and increase IL-10 secretion (second y-axis), respectively. (C) MSCs cultured with mature DC1 cells suppress IFN-γ secretion (first y-axis) by T cells and increase IL-4 levels as compared to MSC or DC alone (No. 1). Second y-axis). Decreased production of pro-inflammatory IFN-γ in the presence of MSCs and increased production of anti-inflammatory IL-4 suggested a variation in the T cell population with respect to the anti-inflammatory phenotype.

Fig. 2 Inhibition of pro-inflammatory effector T cell action of MSCs (A) Non-adherent fraction in PBMCs or MSC + PBMC culture (MSC + PBMC) using FITC-conjugated CD4 antibody (x-axis) and PE-conjugated CD25 antibody (y-axis) Flow cytometric analysis of TReg cell count (%) by minute staining. The gate was set based on the isotype control antibody as background. The graph is representative of 5 independent experiments. (B) In cell culture supernatants, TH1 cells generated in the presence of MSCs secreted a reduced level of IFN-γ (first y-axis), and TH2 cells generated in the presence of MSCs increased. An amount of IL-4 was secreted (second y-axis). (C) MSCs suppress IFN-γ secretion from purified NK cells cultured in 24-well plates for 0, 24, or 48 hours. Data shown are mean ± SD cytokine secretion in one experiment and are representative of three independent experiments.

FIG. 3 Increase in the number of Treg cell populations of MSCs and induction of increased GITR expression (A) CD4 + CD25 + Treg cell populations derived from PRMC or MSC + PBMC (MSC to PBMC ratio 1:10) culture (cultured without further stimulation for 3 days) Was isolated using a two-step magnetic separation method. These cells were irradiated (to prevent further growth) and were used as stimulators in the mixed lymphocyte reaction (MLR). Here, the responders were allogeneic PBMCs in the presence of phytohemagglutinin (PHA) (2.5 mg / ml) (ratio of stimulator to responder 1: 100). The cells were cultured for 48 hours, after which 3H thymidine was added and incorporated radioactivity was counted after 24 hours. The results showed that the Treg population generated in the presence of MSCs (lane 3) is functionally similar to the Treg cells generated in the absence of MSCs (lane 2). (B) PBMCs were cultured in the absence (upper plot) or presence (lower plot) of MSCs (ratio of MSC to PBMC 1:10) for 3 days, after which the non-adhesive fraction was recovered and FITC labeled Immunostained with GITR and PE labeled CD4. The results show a more than 2-fold increase in GITR expression in cells cultured in the presence of MSCs.

Figure 4 Production of PGE2 by MSCs and inhibition of PGE2 that abrogate MSC-mediated immunomodulatory action (A) In the presence or absence of various concentrations of PGE2 inhibitor NS-398 or indomethacin (Indometh.) PGE2 secretion in culture supernatants obtained from cultured MSCs (mean ± SD). The inhibitor concentration is μM and the data presented is the value obtained after 24 hours of culture. (B) COX-1 and COX-2 expression in MSCs and PBMCs using real-time RT-PCR. MSCs expressed much higher levels of COX-2 compared to PBMCs, and when MSCs were cultured in the presence of PBMCs, there was a three-fold increase in MSCs COX-2 expression. Representative data from one of three independent experiments is shown. MSC + PBMC cultures were placed in transwell chamber plates, where MSCs were seeded in the lower chamber and PBMCs were seeded in the upper chamber. (C) Presence of PGE2 inhibitors indomethacin (Ind.) Or NS-398 increased TNF-α secretion from activated DCs and IFN-γ secretion from TH1 cells compared to controls. Data were calculated as% change from cultures that occurred in the absence of MSCs and PGE2 inhibitors. (D) Presence of PGE2 inhibitors indomethacin (Indo) and NS-398 in MSC-PBMC co-culture (1:10) abolishes MSC-mediated antiproliferative effects on PHA-treated PBMCs. The data shown is from one experiment and is representative of three independent experiments.

Figure 5 Increased constitutive MSC cytokine secretion in the presence of allogeneic PBMCs Using pre-characterized human MSCs, the presence of PBMCs (ratio of MSC to PBMC 1:10) (hatched bars) or not The levels of cytokines IL-6 and VEGF, lipid mediator PGE2, and matrix metalloproteinase 1 (pro-MMP-1) were analyzed in the culture supernatant of MSCs cultured in the presence (open bars) for 24 hours. MSCs constitutively produced IL-6, VEGF, and PGE2, and the levels of these factors were increased by co-culture with PBMCs. This indicates that MSCs can be involved in the regulation of immune function in the inflammatory setting.

Figure 6. Suppression of mitogen-induced T cell proliferation in a dose-dependent manner of MSCs. Constants where increasing numbers of allogeneic PBMCs were seeded in 96-well plates in the presence (2.5 mg / ml) or absence of PHA. And 3H thymidine incorporation was measured (in counts / min, i.e. cpm) and incubated with MSCs (2000 cells / well). There was a dose-dependent suppression of the growth of PBMCs treated with PHA in the presence of MSCs. Representative results from one of three independent experiments are shown. Similar results are reported in LeBlanc, et al. , Scan J. Immunol. , Vol. 57, pg. 11 (2003).

Figure 7. Systematic diagram of MSC mechanism of action MSCs are found in cells from both the innate (DCs pathway 2-4; and NK pathway 6) and adaptive (T pathways 1 and 5, and B pathway 7) immune systems. By acting, it regulates its immunomodulatory action. In response to invading pathogens, immature DCs migrate to potential entry sites, mature, and protected (with antigen-specific and costimulatory signals) protective effector T cells (cell-mediated TH1 immunity or humoral TH2 immunity) The ability to prime naive T cells to become During the MSC-DC interaction, MSCs can either interact directly with cell-cell contacts or via secreted factors to limit the ability of DCs to initiate cell-mediated reactions (path 2) or humoral responses. By promoting the ability to initiate (path 4), the result of the immune response may be altered. Also, in the presence of mature effector T cells, MSCs balance the TH1 (path 1) response towards the TH2 response (path 5) and possibly increased IgE-producing B cell activity (path 7), GvHD and They can interact with each other to lean towards the desired outcome for suppression of autoimmune disease symptoms. MSCs can rescue the recipient host by providing a systematic phenotype in the ability to lead to increased development of the TReg population (path 3) and weakening bystander inflammation in the local microenvironment. The dashed line (---) represents the proposed mechanism.

  The invention is disclosed with reference to the following examples. However, it should be understood that the scope of the present invention should not be limited thereby.

Example 1
Materials and Methods Culture of Human MSCs Pittenger et al. , Science, Vol. 284, pg. 143 (1999), human MSCs were cultured. That is, bone marrow samples were collected from the iliac crests of anonymous donors after informed docent by Poetics Technologies, Div of Cambrex Biosciences. MSCs are fully Dulbecco's method containing 1% antibiotic-antimycotic solution (Invitrogen, Carlsbad, California) and 10% fetal bovine serum (FBS, JRH BioSciences, lexexa, Kansas). Cultured in medium (Complete Dulbecco's Modified Eagle's Medium) -low glucose (Life Technologies, Carlsbad, California). MSCs were grown as adherent monolayers and separated using trypsin / EDTA (0.05% trypsin at 37 ° C. for 3 minutes). All the MSCs used were previously revealed for pluripotency and retained the ability to differentiate into the mesenchymal system (cartilage, lipogenesis, and bone formation) (Pittenger et al., Science, Vol. 284, pg. 143 (1999)).

Dendritic Cell Isolation Peripheral blood mononuclear cells (PBMCs) were obtained from Poetics Technologies, Div of Cambrex Biosciences (Walkersville, MD). Monocytic dendritic cell (DCs) precursors (CD1c +) were obtained from Dzionek, et al. , J .; Immunol. , Vol. 165, pg. Positive selection from PBMCs using a two-step magnetic separation method according to 6037 (2000). That is, CD1c-expressing B cells are magnetically removed from CD19 + cells using magnetic beads, and then the B cell removal fraction is labeled using biotin-labeled CD1c (BDCA1 +) and an anti-biotin antibody, Separation from the unlabeled cell fraction using a magnetic column according to the instructions for use (Miltenyi Biotech, Auburn, California). Precursors of plasmacytoid lineages of DCs were isolated from PBMCs by immuno-magnetic sorting of cells (BDCA2 +) coated with positively labeled antibodies (Miltenyi Biotech, Auburn, California).

MSC-DC culture In most experiments, equal numbers of human MSCs and DCs were cultured for various periods, cell culture supernatants were collected and stored at -80 ° C until further experiments. In selected experiments, MSCs were cultured with mature DC1 or DC2 cells (1: 1 MSC: DC ratio) for 3 days, followed by irradiation of mixed cultures (MSCs and DCs) to prevent growth. Subsequently, antibody purification, naive, allogeneic T cells (CD4 +, CD45RA +) were added to irradiated MSCs / DCs and further cultured for 6 days. Thereafter, the nonadherent cell fraction (purified T cells) was collected from the culture medium, washed twice, and restimulated with PHA for 24 hours. Cell culture supernatants were then collected and analyzed for IFN-γ and IL-4 secreted by ELISA.

Isolation of NK cells A purified population of NK cells was purified from biotin-conjugated monoclonal antibodies (anti-CD3, CD14, CD19, CD36 and anti-IgE antibodies) as primary reagents and anti-biotin monoclonals bound to microbeads as secondary labeling reagents. Acquired by removing non-NK cells magnetically labeled with the mixture with the antibody. Magnetically labeled non-NK cells were retained on MACS (Miltenyi Biotech, Auburn, California) columns in the magnetic region, while NK cells were collected by passage.

Isolation of Treg cell populations Treg cell populations were isolated using a two-step isolation method. First, non-CD4 + T cells were indirectly magnetically labeled with a mixture of biotin-labeled antibody and anti-biotin microbeads. Subsequently, the labeled cells were removed by separation on a MACS column (Miltenyi Biotech, Auburn, California). CD4 + CD25 + cells were then directly labeled with CD25 microbeads and isolated from the pre-enriched CD4 + T cell fraction by positive selection. Magnetically labeled CD4 + CD25 + T cells were retained on the column and eluted after removal of the column from the magnetic region.

  To determine whether the increase in the CD4 + CD25 + population that occurred in the presence of MSCs was actually suppressed, the CD4 + CD25 + TReg cell population was transformed into PBMC or MSC + PBMC (ratio of MSC to PBMC 1: 10) Isolated from culture (cultured without further stimulation for 3 days). These cells were irradiated to prevent further growth and were used as stimulators in the mixed lymphocyte reaction (MLR). The responder here was allogeneic PBMCs (ratio of stimulator to responder 1: 100) in the presence of PHA (2.5 μg / ml). A 48 hour incubation was performed, after which 3H thymidine was added and the radioactivity incorporated after 24 hours was counted.

  PBMCs were cultured in the absence or presence of MSCs (MSC to PBMC ratio 1:10), after which the non-adherent fraction was collected and FITC-labeled glucocorticoid-induced TNF receptor, GITR, and PE-labeled CD4 were Used to immunostain.

Generation of TH1 / TH2 cells Peripheral blood mononuclear cells (PBMCs) were seeded at 2 × 10 6 cells / ml for 45 minutes at 37 ° C. to remove monocytes. Non-adhesive fractions were either TH1 (IL-2 (4 ng / ml) + IL-12 (5 ng / ml) + anti-IL-4 (1 μg / ml)) or TH2 (IL− in the presence or absence of MSCs. 2 (4 ng / ml) + IL-4 (4 ng / ml) + anti-IFN-γ (1 μg / ml)), presence of plate-fixed anti-CD3 (5 μg / ml) antibody and anti-CD28 (1 μg / ml) antibody Incubated under for 3 days. Cells were washed and then restimulated with PHA (2.5 μg / ml) for 24 or 48 hours. Thereafter, the levels of IFN-γ and IL-4 in the culture supernatant were measured by ELISA (R & D Systems, Minneapolis, Minnesota).

Analysis of levels of VEGF, PGE2, and pro-MMP-1 in the culture supernatant of MSCs Using pre-specified human MSCs, 24 in the presence or absence of PBMCs (ratio of MSC to PBMC 1:10). The levels of interleukin-6 (IL-6), VEGF, lipid mediator prostaglandin E2 (PGE2), and matrix metalloproteinase 1 (pro-MMP-1) were analyzed in the culture supernatant of time-cultured MSCs. .

Growth of PBMCs Purified PBMCs were treated with centrifuge leucopack (Cambrex, Walkersville, Maryland) on Ficoll-Hypaque (Lymphoprep, Oslo, Norway). The isolated cells were 48 hours in the presence of mitogen PHA (Sigma Chemicals, St. Louis, Missouri) in the presence of MSCs (seeded 3 to 4 hours prior to addition of PBMC to establish) or in the absence. Cultured (in triplicates). In selected experiments, PBMCs were resuspended in media containing the PGE2 inhibitor indomethacin (Sigma Chemicals, St. Louis, Missouri) or NS-938 (Cayman Chemicals, Ann Arbor, Michigan). (3H) -thymidine was added (20 μl in 200 μl culture medium) and cells were collected using an automated collector after an additional 24 hours of culture. The effect of MSCs or PGE2 inhibitor was calculated as a percentage of the control reaction (100%) in the presence of PHA.

Quantitative RT-PCR
Total RNA from the cell pellet was processed using a commercial kit (Qiagen, Valencia, California) and according to the manufacturer's instructions. Contaminated genomic DNA was removed using a DNA free kit (Ambion, Austin, Texas). Quantitect SYBR with 0.5 μM primer
Using the Green RT-PCR kit (Qiagen, Valencia, California), the MJ Research Opticon detection system (South
Quantitative RT-PCR was performed at San Francisco, California). The relative change in expression level in cells cultured under various conditions was calculated by the difference in Ct values (intersection points) using β-actin as an endogenous control. COX-1 and COX-2 specific primer sequences are: COX-1: 5′-CCG GAT GCC AGT CAG GAT GAT G-3 ′ (forward), 5′-CTA GAC AGC CAG ATG CTG ACA G-3 '(Reverse); COX-2: 5'-ATC TAC CCT CCT CAA GTC CC-3' (forward), 5'-TAC CAG AAG GGC AGG ATA CAG-3 '(reverse).

  Increasing numbers of allogeneic PBMCs were incubated in the presence of PHA (2.5 μg / ml) with a constant number of MSCs (2000 cells / well) seeded in 96-well plates for 72 hours, and 3H thymidine incorporation (counts / minute) I.e. in cpm).

  PBMCs and MSCs were cultured at a ratio of 1: 1, 1: 3, 1:10, 1:30, and 1:81 of MSC: PBMC.

Results In this study, the interaction of human MSCs with isolated immune cell populations including dendritic cells (DC1 and DC2), effector T cells (TH1 and TH2), and NK cells was investigated. The interaction of MSCs with each immune cell type was a specific result indicating that MSCs can regulate multiple stages of the immune response process. Production of secreted factors that regulate MSC immunomodulatory activity and can cause MSC immunomodulatory activity has been evaluated and shown to involve prostaglandin synthesis.

  Bone marrow (DC1) progenitor dendritic cells and plasmacytoid (DC2) progenitor dendritic cells were isolated by immuno-magnetic sorting of BDCA1 + and BDCA2 + cells, respectively, with GM-CSF and IL-4 (1 each for DC1 cells) DC2 cells were matured by incubating with IL-3 (10 ng / ml) together with (× 10 3 IU / ml and 1 × 10 3 IU / ml). Using flow cytometry, DC1 cells were HLA-DR + and CD11c +, while DC2 cells were HLA-DR + and CD123 + (FIG. 1A). In the presence of the inflammatory factor bacterial lipopolysaccharide (LPS, 1 ng / ml), DC1 cells produced moderate levels of TNF-α, but when MSCs were present (1: 1 and 1:10). There was a more than 50% decrease in TNF-α secretion (Fig. 1B). On the other hand, DC2 cells produced IL-10 in the presence of LPS, and the level increased more than 2-fold with MSC: DC2 co-culture (1: 1) (FIG. 1B). Therefore, MSCs changed the cytokine profile of activated DCs in culture to a more permissive protozoan phenotype. Furthermore, activated DCs can decrease IFN-γ and increase IL-4 levels secreted by naive CD4 + T cells when cultured with MSCs (FIG. 1C), which is pro-inflammatory. FIG. 6 shows MSC-mediated changes from a T cell phenotype to an anti-inflammatory T cell phenotype.

  Since increased secretion of IL-10 is involved in the development of regulatory cells (Kingsley, et al., J. Immunol., Vol. 168, pg. 1080 (2000)), T regulatory cells (TReg) can be transformed into PBMCs. And quantified by flow cytometry in co-cultures of MSCs. Incubation of PBMCs with MSCs for 3 to 5 days resulted in an increase in the number of TReg cells measured by staining of PBMCs with anti-CD4 and anti-CD25 antibodies (FIG. 2A), further supporting the MSC-induced tolerant progenitor response. . The CD4 + CD25 + TReg cell population generated in the presence of MSCs expressed increased levels of glucocorticoid-induced TNF receptor (GITR), a cell surface receptor expressed on the TReg cell population, and also suppressed allogeneic T cell proliferation ( 3A and 3B), it was actually inhibitory. Next, MSCs were investigated for direct ability to affect T cell differentiation. Using antibody-selected purified T cells (CD4 + Th cells), IFN-γ producing TH1 cells and IL-4 producing TH2 cells were generated in the presence or absence of MSCs. The presence of MSCs during differentiation decreased IFN-γ secretion by TH1 cells and increased IL-4 secretion by TH2 cells (FIG. 2B). No significant change in IFN-γ or IL-4 levels was seen when MSCs were added to the culture after Th cells differentiated into effector TH1 or TH2 type (3 days) (not shown) . These experiments indicate that MSCs can directly affect effector T cell differentiation and change T cell cytokine secretion to a humoral phenotype.

  Similarly, when MSCs were cultured with purified NK cells (CD3-, CD14-, CD19-, CD36-) at a ratio of 1: 1 for different periods (0 to 48 hours), the decrease in IFN-γ secretion in the culture supernatant (FIG. 2C). This therefore indicates that MSCs can also regulate NK cell action.

  Previous studies have shown that MSCs regulate T cell action by water-soluble factors (LeBlanc, et al., Exp. Hematol., Vol. 31, pg. 890 (2003); Tse, et al. , Transplantation, Vol. 75, pg. 389 (2003)). It was observed that MSCs constitutively secreted multiple factors including IL-6, prostaglandin E2, VEGF, and proMMP-1, with each level increased by cultures containing PBMCs (FIG. 5). . In order to investigate the MSC generator that leads to the suppression of TNF-α production and increased IL-10 production by DCs, the potential role of prostaglandin E2 was investigated, but TNF-γ production by activated DCs was investigated. Inhibition was observed (Vassiliou, et al., Cell. Immunol., Vol. 223, pg. 120 (2003)). The conditioned medium for MSC culture (24 hours culture at 0.5 × 10 6 cells / ml) contained approximately 1000 pg / ml PGE2 (FIG. 4A). The presence of a known inducer of PGE2 secretion, such as TNF-α, IFN-γ or IL-1β, in the culture supernatant (not shown) could not be detected, indicating constitutive secretion of PGE2 by MSCs . PGE2 secretion by hMSCs was suppressed 60-90% in the presence of known inhibitors of PGE2 production, NS-398 (5 μM) and indomethacin (4 μM) (FIG. 4A). Because the release of PGE2 secretion occurs as a result of the enzymatic activity of constitutively active cyclooxygenase enzyme 1 (COX-1) and inducible cyclooxygenase enzyme 2 (COX-2) (Harris, et al., Trends Immunol., Vol. 23). , Pg. 144 (2002)), COX-1 and COX-2 mRNA expression in MSCs and PBMCs was analyzed using a transwell culture system. MSCs express much higher levels of COX-2 compared to PBMCs, and in the case of 24-hour co-culture of MSCs and PBMCs (ratio of MSC to PBMC 1:10), expression levels are more than 3-fold Increased (FIG. 4B). A slight change in COX-1 levels was seen, indicating that the increase in PGE2 secretion by MSC-PBMC co-culture (FIG. 5) is regulated by upward regulation of COX-2. In order to investigate whether the immunomodulatory effect of MSC on DCs and T cells was regulated by PGE2, MSCs activated dendritic cells (DC1) or TH1 cells in the presence of PGE2 inhibitor NS-398 or indomethacin Incubated with. The presence of NS-398 or indomethacin increased TNF-α secretion by DC1s and IFN-γ secretion from TH1 cells (FIG. 4C), which secreted the effect of MSC on immune cell types. It shows that it can be regulated by PGE2. Recent studies have shown that MSCs suppress T cell proliferation induced by various stimuli (Denicola, et al., Blood, Vol. 99, pg. 3838 (2002); LeBlanc, et al.,). Scand. J. Immunol., Vol. 57, pg. 11 (2003)). MSCs were observed to suppress mitogen-induced T cell proliferation in a dose-dependent manner (FIG. 6), and in the presence of PGE2 inhibitor NS-398 (5 μM) or indomethacin (4 μM) 3H thymidine incorporation by PHA-treated PBMCs increased by more than 70% compared to controls without inhibitor (FIG. 4D).

  In summary, a model for the interaction of MSCs with other immune cell types (FIG. 7) is proposed. When mature T cells are present, MSCs interact directly with them to suppress proinflammatory IFN-γ production (path 1), promote a regulatory T cell phenotype (path 3), It also promotes anti-inflammatory TH2 cells (path 5). Furthermore, MSCs secrete PGE2, suppress pro-inflammatory DC1 cells (path 2), and promote anti-inflammatory DC2 cells (path 4) or regulatory DCs (path 3), thereby mediated DCs. The results of the T cell immune response can be altered. In other words, the change to TH2 immunity indicates a change in B cell activity to increased development of IgE / IgG1 subtype antibodies (pathway 7). MSCs can regulate NK cell action by their ability to suppress IFN-γ secretion from NK cells (pathway 6). This model of MSC: immune cell interactions are consistent with experiments performed at several other laboratories (LeBlanc, et al., Exp. Hematol., Vol. 31, pg. 890 (2003); Tse, et al., Transplantation, Vol.75, pg.389 (2003); DiNicola, et al., Blood, Vol.99, pg.3838 (2002)). Further investigation of the proposed mechanism is ongoing and now animal studies are needed to investigate the in vivo effects of MSC administration.

All patents, including published patent applications, storage registration numbers, and database registration numbers;
The literature is incorporated herein by reference to the same extent as each patent, literature, storage registration number, and database registration number are explicitly and individually incorporated by reference.

  However, it should be understood that the scope of the present invention should not be limited to the particular embodiments described above. The invention may be practiced otherwise than as specifically disclosed, which are also within the scope of the appended claims.

However, it should be understood that the scope of the present invention should not be limited to the particular embodiments described above. The invention may be practiced otherwise than as specifically disclosed, which are also within the scope of the appended claims.
Aspects of the Invention [1] An isolated, allogeneic, non-genetically engineered mesenchyme for the manufacture of a pharmaceutical preparation characterized by promoting angiogenesis in an organ or tissue other than the heart of an animal Stem cell usage.
[2] The method according to [1], wherein the animal is a mammal.
[3] The method according to [2], wherein the animal is a primate.
[4] The method according to [3], wherein the primate is a human.
[5] The use according to [1], wherein the mesenchymal stem cells of the pharmaceutical preparation are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg.
[6] The use according to [1], wherein the mesenchymal stem cells of the pharmaceutical preparation are administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg.
[7] The use according to [1], wherein the mesenchymal stem cells of the pharmaceutical preparation are administered systemically.
[8] The method according to [1], wherein the mesenchymal stem cells of the pharmaceutical preparation are administered intravenously.
[9] The method according to [1], wherein the mesenchymal stem cells of the pharmaceutical preparation are administered by direct injection into an organ or tissue other than the heart of the animal.
[10] Use of isolated, allogeneic, unengineered mesenchymal stem cells for the manufacture of a pharmaceutical preparation characterized by treating an autoimmune disease in an animal.
[11] The use according to [10], wherein the animal is a mammal.
[12] The method according to [11], wherein the mammal is a human.
[13] Use of isolated, allogeneic, non-engineered mesenchymal stem cells for the manufacture of a pharmaceutical formulation characterized by treating an inflammatory response in an animal, comprising: Treatment of inflammatory response reduces inflammation in brain, skin, gastrointestinal tract (in inflammatory colitis), liver (in chronic hepatitis), eyes, spinal cord, pregnancy uterus and placenta, ovary, testis, adrenal cortex or hair follicle Including usage.
[14] The use according to [13], wherein the inflammatory reaction is inflammatory colitis.
[15] The use according to [13], wherein the isolated allogeneic non-genetically-engineered mesenchymal stem cells limit or reduce intestinal inflammation.
[16] The use according to [13], wherein the animal is a mammal.
[17] The use according to [16], wherein the mammal is a human.
[18] The use according to [13], wherein the inflammatory reaction is related to psoriasis.
[19] Use of isolated, allogeneic, unengineered mesenchymal stem cells for the manufacture of a pharmaceutical formulation characterized by treating cancer in an animal, wherein said Use, wherein mesenchymal stem cells inhibit tumor growth.
[20] The method according to [19], wherein the animal is a mammal.
[21] The use according to [20], wherein the mammal is a human.
[22] Use of isolated, allogeneic, not genetically engineered mesenchymal stem cells for the manufacture of a pharmaceutical preparation for treating an allergic disease or symptom of an animal.
[23] The use according to [22], wherein the animal is a mammal.
[24] The use according to [23], wherein the mammal is a human.
[25] The use according to [22], wherein the allergic disease or allergic symptom is arthritis.
[26] Use of isolated, allogeneic, unengineered mesenchymal stem cells for the manufacture of a pharmaceutical formulation characterized in promoting animal wound healing.
[27] The method according to [26], wherein the animal is a mammal.
[28] The use according to [27], wherein the mammal is a human.
[29] The use according to [26], wherein the wound is selected from the group consisting of a burn, a cut and a laceration.
[30] Use of human, isolated, allogeneic, unengineered mesenchymal stem cells for the manufacture of a pharmaceutical preparation characterized by preventing fibrosis in animals.

Claims (30)

  Use of an isolated, allogeneic, non-engineered mesenchymal stem cell for the manufacture of a pharmaceutical preparation characterized in that it promotes angiogenesis in organs or tissues other than the heart of an animal.   The use according to claim 1, wherein the animal is a mammal.   The use according to claim 2, wherein the animal is a primate.   4. Use according to claim 3, wherein the primate is a human. The use according to claim 1, wherein the mesenchymal stem cells of the pharmaceutical preparation are administered in an amount of about 1 x 10 ⁵ cells / kg to about 1 x 10 ⁷ cells / kg. The use according to claim 1, wherein the mesenchymal stem cells of the pharmaceutical preparation are administered in an amount of about 1 x 10 ⁶ cells / kg to about 5 x 10 ⁶ cells / kg.   The use according to claim 1, wherein the mesenchymal stem cells of the pharmaceutical preparation are administered systemically.   The use according to claim 1, wherein the mesenchymal stem cells of the pharmaceutical preparation are administered intravenously.   The use according to claim 1, wherein the mesenchymal stem cells of the pharmaceutical preparation are administered by direct injection into an organ or tissue other than the heart of the animal.   Use of isolated, allogeneic, non-engineered mesenchymal stem cells for the manufacture of a pharmaceutical preparation characterized in treating an autoimmune disease of an animal.   The use according to claim 10, wherein the animal is a mammal.   The use according to claim 11, wherein the mammal is a human.   Use of an isolated, allogeneic, non-engineered mesenchymal stem cell for the manufacture of a pharmaceutical formulation characterized by treating an inflammatory response in an animal, wherein Treatment includes reducing inflammation in the brain, skin, gastrointestinal tract (in inflammatory colitis), liver (in chronic hepatitis), eyes, spinal cord, pregnancy uterus and placenta, ovary, testis, adrenal cortex or hair follicle ,how to use.   The use according to claim 13, wherein the inflammatory reaction is inflammatory bowel disease.   14. The use according to claim 13, wherein the isolated, allogeneic, non-engineered mesenchymal stem cells limit or reduce intestinal inflammation.   14. The use according to claim 13, wherein the animal is a mammal.   The use according to claim 16, wherein the mammal is a human. 14. The use according to claim 13, wherein the inflammatory response is associated with psoriasis.   Use of an isolated, allogeneic, non-engineered mesenchymal stem cell for the manufacture of a pharmaceutical preparation characterized in treating animal cancer, wherein said mesenchymal stem cell That suppresses tumor growth.   The use according to claim 19, wherein the animal is a mammal.   21. The use according to claim 20, wherein the mammal is a human.   Use of isolated, allogeneic, not genetically engineered mesenchymal stem cells for the manufacture of a pharmaceutical preparation for treating an allergic disease or allergic condition in animals.   The use according to claim 22, characterized in that the animal is a mammal.   24. Use according to claim 23, characterized in that the mammal is a human.   23. Use according to claim 22, characterized in that the allergic disease or allergic condition is arthritis.   Use of isolated, allogeneic, unengineered mesenchymal stem cells for the manufacture of a pharmaceutical formulation characterized in promoting animal wound healing.   27. The use according to claim 26, wherein the animal is a mammal.   28. The use according to claim 27, wherein the mammal is a human.   27. Use according to claim 26, characterized in that the wound is selected from the group consisting of burns, cuts and lacerations.   Use of human, isolated, allogeneic, unengineered mesenchymal stem cells for the manufacture of a pharmaceutical formulation characterized in preventing animal fibrosis.

Images